A phase I study of sorafenib, oxaliplatin and two days of high dose capecitabine in advanced pancreatic and biliary tract cancer: A Wisconsin Oncology Network Study

Chemotherapy has yielded minimal clinical benefit in pancreatic and biliary tract cancer. A high-dose, short course capecitabine schedule with oxaliplatin, has shown some efficacy with a lower incidence of palmar-plantar erythrodysesthesia. Achieving high exposures of the targeted agent sorafenib ma...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: LoConte, Noelle K., Holen, Kyle D., Schelman, William R., Mulkerin, Daniel L., Deming, Dustin A., Hernan, Hilary R., Traynor, Anne M., Goggins, Timothy, Groteluschen, David, Oettel, Kurt, Robinson, Emily, Lubner, Sam J.
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199231/
https://ncbi.nlm.nih.gov/pubmed/23263993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9916-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires